ストックスクリーナーアプリを入手
5.15
1.90%
-0.10
Coya Therapeutics Inc (COYA) 最新ニュース
Coya Therapeutics: Clinical Momentum, Extended Cash Runway, and DCF-Derived Upside Support Reiterated Buy and $18 Target - TipRanks
Coya Therapeutics (NASDAQ:COYA) Given Buy Rating at D. Boral Capital - Defense World
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for CO - PharmiWeb.com
Coya Therapeutics announces FDA acceptance of COYA 302 IND application - TipRanks
COYA Stock Receives Consistent "Buy" Rating from D. Boral Capita - GuruFocus
D. Boral Capital Reiterates "Buy" Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
US COYA 302 trial in ALS expands to Canada after regulatory nod - ALS News Today
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD) - The Joplin Globe
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for COYA 302 for the Treatment of Frontotemporal Dementia - MarketScreener
H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock at $18 - Investing.com UK
(COYA) Risk Channels and Responsive Allocation - Stock Traders Daily
Coya announces Health Canada acceptance of COYA 302 clinical trial application - MSN
S P Trends: Will Coya Therapeutics Inc stock pay special dividendsJuly 2025 Price Swings & Long-Term Safe Return Strategies - moha.gov.vn
Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - BioSpace
Trading the Move, Not the Narrative: (COYA) Edition - Stock Traders Daily
D. Boral Capital Maintains Coya Therapeutics (COYA) Buy Recommendation - Nasdaq
D. Boral Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Coya Therapeutics receives clinical trial application acceptance from Health Canada - marketscreener.com
Coya Therapeutics, Inc. Receives Clinical Trial Application Acceptance from Health Canada to Proceed with the COYA302 Alstars Trial for the Treatment of Amyotrophic Lateral Sclerosis - marketscreener.com
Moving Averages: Why retail investors pile into Coya Therapeutics Inc. stockEarnings Recap Report & Reliable Entry Point Alerts - Улправда
Why retail investors pile into Coya Therapeutics Inc. stock2025 Trading Volume Trends & Low Volatility Stock Recommendations - Улправда
Analyst Upgrade: Is Coya Therapeutics Inc. stock a bargain at current levels2025 Volatility Report & Capital Protection Trading Alerts - DonanımHaber
Can Coya Therapeutics Inc. stock maintain operating marginsJuly 2025 Big Picture & Safe Capital Investment Plans - Улправда
Coya Therapeutics Receives $4.2M Milestone Payment - TipRanks
Coya Therapeutics Receives Milestone Payment for ALS Trial - TradingView — Track All Markets
Coya Therapeutics (NASDAQ: COYA) reports $4.2 million ALS trial payment - Stock Titan
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives $16.00 Average Price Target from Brokerages - Defense World
Coya Therapeutics receives $4.2M milestone payment - MSN
Coya Therapeutics Earnings Notes - Trefis
Coya Therapeutics, Inc. (NASDAQ:COYA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Responsive Playbooks and the COYA Inflection - Stock Traders Daily
H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock By Investing.com - Investing.com Canada
Buy Rating for Coya: Phase 2 Trial Initiation and Financial Milestones Boost Prospects - TipRanks
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS - BioSpace
Coya Therapeutics, Inc.: Promising Advancements in ALS and FTD Treatment with COYA-302 - TipRanks
Coya Therapeutics Announces Patients Have Been Dosed in the Alstars Trial of Coya 302 for the Treatment of Als - marketscreener.com
Coya Therapeutics' (COYA) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
Eisai Still Confident in Anti-Tau Asset as J&J Becomes Latest Victim in Spiraling Space - BioSpace
Analysts Are Bullish on Top Healthcare Stocks: vTv Therapeutics (VTVT), Theravance Biopharma (TBPH) - The Globe and Mail
Coya Therapeutics (COYA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Understanding the Setup: (COYA) and Scalable Risk - Stock Traders Daily
Investor Presentation (12/01/2025 00: 00 - marketscreener.com
Highs Report: Is Coya Therapeutics Inc. stock a top momentum play2025 Growth vs Value & Advanced Swing Trade Entry Plans - BỘ NỘI VỤ
HC Wainwright Lifts Earnings Estimates for Coya Therapeutics - MarketBeat
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences - BioSpace
Form 424B5Prospectus [Rule 424(b)(5)] - ADVFN
H.C. Wainwright Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $18 - 富途牛牛
H.C. Wainwright reaffirms Buy rating on Coya Therapeutics stock at $18 target - Investing.com Canada
Coya Therapeutics: Strong Financial Position and Upcoming Catalysts Support Buy Rating - TipRanks
What drives Coya Therapeutics Inc stock pricePortfolio Risk Assessment & Outstanding Growth Portfolio - earlytimes.in
D. Boral Capital Initiates Coverage of Coya Therapeutics (COYA) with Buy Recommendation - MSN
Is Coya Therapeutics Inc. stock a buy before product launchesJuly 2025 Outlook & Short-Term Trading Alerts - newser.com
Is Coya Therapeutics Inc. stock cheap at current valuationJuly 2025 Catalysts & Daily Risk Controlled Trade Plans - newser.com
The Technical Signals Behind (COYA) That Institutions Follow - news.stocktradersdaily.com
Can Coya Therapeutics Inc. stock weather global recessionBull Run & Risk Controlled Stock Pick Alerts - newser.com
28.63%
大文字化:
|
ボリューム (24 時間):